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Abstract
Background: In Australia in June 2001, a unique pneumococcal vaccine schedule commenced for
Indigenous infants; seven-valent pneumococcal conjugate vaccine (7PCV) given at 2, 4, and 6
months of age and 23-valent pneumococcal polysaccharide vaccine (23PPV) at 18 months of age.
This study presents carriage serotypes following this schedule.
Methods: We conducted cross sectional surveys of pneumococcal carriage in Aboriginal children
0 to 6 years of age living in remote Aboriginal communities (RACs) in 2003 and 2005. Nasal
secretions were collected and processed according to published methods.
Results: 902 children (mean age 25 months) living in 29 communities in 2003 and 818 children
(mean age 35 months) in 17 communities in 2005 were enrolled. 87% children in 2003 and 96% in
2005 had received two or more doses of 7PCV. From 2003 to 2005, pneumococcal carriage was
reduced from 82% to 76% and reductions were apparent in all age groups; 7PCV-type carriage was
reduced from 11% to 8%, and 23PPV-non-7PCV-type carriage from 31% to 25% respectively. Thus
non-23PPV-type carriage increased from 57% to 67%. All these changes were statistically significant,
as were changes for some specific serotypes. Shifts could not be attributed to vaccination alone.
The top 10 of 40 serotypes identified were (in descending order) 16F, 19A, 11A, 6C, 23B, 19F, 6A,
35B, 6B, 10A and 35B. Carriage of penicillin non-susceptible (MIC > = 0.12 μg/mL) strains (15%
overall) was detected in serotypes (descending order) 19A, 19F, 6B, 16F, 11A, 9V, 23B, and in 4
additional serotypes. Carriage of azithromycin resistant (MIC > = 2 μg/mL) strains (5% overall), was
detected in serotypes (descending order) 23B, 17F, 9N, 6B, 6A, 11A, 23F, and in 10 additional
serotypes including 6C.
Published: 4 August 2009
BMC Infectious Diseases 2009, 9:121 doi:10.1186/1471-2334-9-121
Received: 28 November 2008
Accepted: 4 August 2009
This article is available from: http://www.biomedcentral.com/1471-2334/9/121
© 2009 Leach et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 9
(page number not for citation purposes)
BMC Infectious Diseases 2009, 9:121 http://www.biomedcentral.com/1471-2334/9/121Conclusion: Pneumococcal carriage remains high (~80%) in this vaccinated population. Uptake of
both pneumococcal vaccines increased, and carriage was reduced between 2003 and 2005.
Predominant serotypes in combined years were 16F, 19A, 11A, 6C and 23B. Antimicrobial non-
susceptibility was detected in these and 17 additional serotypes. Shifts in serotype-specific carriage
suggest a need more research to clarify the association between pneumococcal vaccination and
carriage at the serotype level.
Background
Australian Aboriginal children in remote communities
experience high rates of many infectious diseases[1,2],
particularly pneumococcal disease.[3] Concern about
antibiotic resistance is used as an argument against greater
use of antibiotics. Recent reports describe escalating rates
of disease caused by pneumococcal serotypes not
included in currently licensed pneumococcal conjugate
vaccine (7PCV),[3,4]including an increasing proportion
of isolates having antibiotic resistance. [5-7] Serotype 19A
is of particular interest in Australia[3] and internation-
ally.[8] More recent data suggests 6C as a new and emerg-
ing replacement serotype, and that 7PCV is cross-
protective for 6A. Prior to 7PCV introduction in 2001,[9]
pneumococcal carriage in Indigenous infants was around
80% and approximately 60% were 7PCV serotypes
(unpublished data from 3 of the communities also in
these surveys). In 2003 and 2005 we conducted wider
geographic surveillance of pneumococcal carriage.
Methods
Vaccine schedule
From July 2001 7PCV was recommended and funded for
Australian Aboriginal and other high-risk infants at 2, 4
and 6 months of age. In the Northern Territory and in
South Australia, 23-valent pneumococcal polysaccharide
vaccine (23PPV) was recommended as a booster dose for
Aboriginal children at 18 months of age.[9] Children less
than 2 years of age were offered catch-up 7PCV.
Study setting and participant eligibility criteria
Participating communities were in four regions of South
Australia and the Northern Territory. Children were eligi-
ble if they were Aboriginal, 0 to 6 years of age, resident in
a participating community, and if their parents or car-
egiver provided written consent.
Swab collection, antibiotic use and vaccination history
Nasal secretions were collected using swabs or nose blow-
ing into a tissue as previously described.[10,11] Pneumo-
coccal vaccination dates and antibiotics prescribed in the
5 weeks prior to swab collection were obtained from the
NT childhood immunization register and participant
medical records.
Microbiological analysis
Nasal secretions were transported, stored and processed as
previously described.[10] Pneumococci were identified
and one or more colonies (if morphologically distinct)
selected for serotyping with antisera from the Statens
Serum Institute (Denmark). Antimicrobial susceptibility
was determined by disc diffusion[12] and Etest (AB Bio-
disk, Sweden). We performed PCR for the wciN gene.[13]
Statistical analysis
Confidence intervals (CI, 95%) and risk differences (RD,
with 95% CI) were calculated where appropriate. Stata
version 10 was used for all data analysis[14]
Ethical Approval and Funding
The study was approved by the regional Human Research
Ethics Committees and Aboriginal Sub-Committee with
right of veto of the Northern Territory Department of
Health and Community Services and Menzies School of
Health Research. The study was funded by the National
Health and Medical Research Council.
Results
Participant characteristics
Nasal secretions were collected from 902 children in 29
communities in 2003 and from 818 children in 17 com-
munities in 2005 (Table 1). Nasal swabs comprised 94%
specimens. Mean age was 30 months. 83 were less than 6
months of age.
Vaccine uptake
In 2003 87% children had received at least 2 doses of
7PCV (Table 2). In 2005, this figure was 96% (Risk Differ-
ence = 9% [95% Confidence Interval 7,12]). The propor-
tion of children receiving a full primary 7PCV plus booster
Table 1: Participant characteristics
2003 2005 Total
No. Children 902 818 1720
Mean age in months (95% CI) 25 (24–26) 35 (33–36) 30.0 (29–31)
Sex male (%) 447 (50%) 403 (49%) 850 (49%)Page 2 of 9
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[22,31]) (Tables 2 and 3). 169 children had no record of
receiving either 7PCV or 23PPV. Ten children had 23PPV
only. Of the 83 infants less than 6 months of age, 59
(71%) had received at least one dose of 7PCV.
Carriage
Pneumococcal carriage in 2003 and 2005 combined was
79%. There was no difference in pneumococcal recovery
between nasal swab (79%) and nose blowing (80%) col-
lection methods. Pneumococcal carriage declined overall
from 82% in 2003 to 76% in 2005 (RD = -6% [-10, -2] p
= 0.0037), and similar reductions were seen in all age
groups (Table 2). However this was not seen in all regions
(Table 3).
Carriage in children seen in both surveys
Of the 226 children seen in both surveys, 80% were posi-
tive each year, and 148 (65%) were carriage positive in
both 2003 and 2005; only 11 carried the same serotype.
Carriage in communities seen only in 2003
In the 12 communities seen only in 2003, 106 (82%) of
130 children were carriage positive, 5% carried azithro-
mycin resistant strains (MIC > = 2 μg/mL) and 23% car-
ried penicillin non-susceptible strains (MIC > = 0.12 μg/
mL). Carriage and resistance in the other 17 communities
seen in 2003 was 82%, 5% and 17%, respectively.
Serotype-specific carriage
7PCV-type carriage was 11% in 2003 and 8% in 2005 (RD
= -4% [-6, -0.1] p = 0.0105) (Table 2). 23PPV -non-7PCV-
type carriage was 42% in 2003 and 33% in 2005 (RD = -
6% [-10,-2] p = 0.0061]). Reductions reached statistical
significance for serotypes 6B and 19A. Non-23PPV-type
carriage increased overall (RD = 9% [CI 5,14] p = 0.0001)
and reached statistically significance for non-vaccine types
23B, 23A, 34 and 10F, and for 23PPV types 20 and 9N. Of
the isolates serotyped, the predominant carriage serotypes
were 16F(14%), 19A(13%), and 11A (6.5%) and 6C (6%)
(see Figure 1).
Non-vaccinated children
In 2003 and 2005, carriage in 169 non-vaccinated chil-
dren (no 7PCV or 23PPV) was 74% and 70% respectively;
carriage of 7PCV types was 9% and 7%, 23PPV-non-7PCV
types was 19% and 24%. Predominant serotypes were
16F(10%) and 19A(9%) followed by 6% each of 11A, 6C,
23B and 22F.
Table 2: Vaccination status, pneumococcal carriage by serotype, recent antibiotic use and carriage of non-susceptible pneumococci, by 
year
Year 2003 2005
No. communities 29 17
No. children swabbed 902 818
Children (%) Risk Difference P
Vaccinated (>1 dose) 87% 96% 9% [7,12] 0.0000
Vaccinated (primary) 76% 84% 9% [5,12] 0.0000
Vaccinated (primary+23v) 35% 62% 27% [22,31] 0.0000
Spn (% children) 82% 76% -6% [-10,-2] 0.002
0–6 mo n = 83 83% 74% -9.7 [-28,8] 0.3098
6–12 mo n = 220 80% 78% -1.6 [-13,10] 0.7791
12–24 mo n = 477 84% 76% -8.2 [-16, -0.2] 0.0331
24–48 mo n = 597 84% 78% -5.3 [-12,1] 0.0989
48- n = 343 77% 74% -2.9 [-13,7] 0.5677
7PCV-type 11% 8% -4% [-6, -0.1] 0.0105
23PPV-type 42% 33% -9% [-14,-5] 0.0001
23PPV-type, non-7PCV 31% 25% -6% [-10,-2] 0.0061
19A 12% 9% -3% [-6,-1] 0.0196
Non-23PPV 57% 67% 9% [5,14] 0.0001
6A 4% 2% -1.5% [-3,0.1] 0.0712
6C 4% 4% 0% [-2,2] 0.9634
16F 12% 10% -2% [-5,1] 0.1343
Prescribed beta-lactam 14% 16% 1% [-2,5] 0.4763
Penicillin non-susceptible (MIC ≥ 0.12 μg/mL) 17% 14% -3% [-6,0.4] 0.0899
Prescribed macrolide 1% 6% 5% [3,7] 0.0000
Azithromycin resistant (MIC ≥ 2 μg/mL) 5% 6% 1% [-1,3] 0.4888
Azithromycin resistant (MIC ≥ 32 μg/mL) 4% 3% -1% [-3,1] 0.2328Page 3 of 9
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Carriage in 83 infants less than 6 months of age was 83%
in 2003 and 74% in 2005 (RD = -10% [-28, 8]). Carriage
of 7PCV types was 20% and 4%, respectively (RD = -16%
[-31, -1]). Predominant serotypes were 19A(17%),
16F(14%), 6A(8%) and 11A(8%) followed by 6B, 15C
and 22F.
Non-vaccinated infants less than 6 months of age
For 24 non-vaccinated infants less than 6 months of age
(mean age 1.9 months), carriage was 43% (3/7) and 65%
(11/17) in 2003 and 2005, respectively (RD = 22% [-21,
65]). The 2003 serotypes were 6B, 11A and 20. The 2005
serotypes were 6A and 6C(2) and one each of 10F, 11A,
13, 18A, 19A, 19F, 33F, 34, and 22F.
23PPV vaccinated children
Although carriage of 23PPV-non-7PCV types declined
from 2003 to 2005, this could not be explained by the rise
in 23PPV uptake. For both years combined, among chil-
dren more than 18 months of age, carriage of 23PPV-non-
7PCV types was 30% in 23PPV-vaccinated children com-
pared to 26% in non-vaccinated children (RD = 4% [-
2,10]). This difference was statistically significant in 2003
(RD = 11% [3,19]), but not in 2005 (RD = -1% [-12,9]).
At the serotype level, these trends were present for sero-
type 19A but did not reach statistical significance.
Table 3: Pneumococcal (Spn) carriage, 7-valent pneumococcal conjugate vaccine (7PCV) uptake, carriage of 7PCV and 23PPV types, 
recent antimicrobial use, and carriage of non-susceptible pneumococci in children 0 to 6 years of age, by region and year.
Region Central Australia Darwin Rural¥ East Arnhem Katherine West
Year 2003 2005 2003 2005 2003 2005 2003 2005
No. communities 11 2 6 6 7 4 5 5
No. children swabbed 158 65 320 376 315 223 109 154
Percent children (95% Confidence Interval)
Spn positive 83(77–89) 86(78–95) 79(75–84) 67(62–72)* 85(81–89) 87(83–92) 82(74–89) 78(71–85)
Vaccinated (> = 1 dose) 96(93–99) 97(93–101) 88(84–91) 96(94–98)* 80(76–84) 97(95–99)* 89(83–95) 94(90–98)
Vaccinated (primary) 85(79–90) 83(74–92) 79(75–84) 87(84–90)* 71(66–76) 82(77–87)* 70(61–78) 82(76–89)
Vaccinated (primary+23v) 46(39–54) 54(41–66) 34(29–39) 65(60–69)* 30(24–34) 59(52–65)* 39(29–48) 62(54–69)*
7PCV-type positive 10(5–14) 12(4–21) 15(11–19) 9(6–12) 10(7–13) 10(6–14) 6(2–11) 3(0–5)
Serotype in 23PPV not in 7PCV 41(33–49) 40(29–52) 33(27–38) 25(21–29) 26(21–33) 23(17–28) 30(22–39) 31(23–38)
19A 14(8–19) 15(6–24) 17(12–21) 10(7–13) 8(5–11) 6(3–9) 5(1–9) 10(5–14)
6A 0.6(-1–2) 3(-1–7) 3(1–5) 2(0–3) 6(4–9) 4(2–7) 6(1–10) 1(0–3)
6C 3(0–6) 2(-2–5) 4(2–7) 3(1–5) 6(3–8) 7(3–10) 2(-1–4) 5(2–9)
16F 10(5–15) 11(3–19) 12(8–15) 12(8–15) 11(7–14) 10(6–14) 19(12–27) 6(2–9)*
Prescribed beta-lactam 28(21–35) 38(26–51) 17(13–21) 16(12–20) 7(4–9) 12(7–16) 9(4–15) 10(5–14)
Penicillin non-susceptible 
(MIC ≥ 0.12 μg/mL)
25(19–32) 42(29–54) 18(14–22) 9(6–12)* 14(10–18) 16(11–21) 13(6–19) 13(8–18)
Prescribed macrolide 0 2(-2–5) 3(1–5) 13(9–16)* 0 0 2(-1–4) 2(0–4)
Azithromycin resistant 
(MIC ≥ 2 μg/mL)
9(4–12) 22(11–32) 3(1–5) 5(3–8) 3(1–4) 3(1–5) 11(5–17) 5(1–8)
*95% confidence interval not overlapping with previous year. MIC = Minimum inhibitory concentration.
¥Note: One large community had participated in a trachoma eradication program involving mass azithromycin treatment in the weeks before our 
2005 survey; carriage was 48% (22/45) in children with a record of recent treatment and 51% (36/70) in children with no record of recent 
treatment.Page 4 of 9
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Beta-lactam antibiotics had been recently prescribed
(within 5 weeks prior to swabbing) for 14% children in
2003 and for 16% in 2005 (Tables 2 and 3). In general,
macrolides were rarely recently prescribed with the excep-
tion of 48 of 396 (13%) children the Darwin Rural region
(Table 3). Of these 48 children, 45 were from one com-
munity and had been prescribed azithromycin for tra-
choma eradication.
Antibiotic resistance
Carriage of penicillin non-susceptible pneumococci (MIC
≥ 0.12 μg/mL) was 17% in 2003 and 14% in 2005 (Table
2). In Central Australia where prescribing was highest, car-
riage was 25% in 2003 and 42% in 2005 (Table 3). Peni-
cillin resistance of 1.0 μg/mL or more was found in six
children from 3 communities, all were serotype 9 V. Azi-
thromycin resistant pneumococci (MIC ≥ 2 μg/mL) were
carried by 5% children in 2003 and 6% in 2005. In the
community where mass azithromycin had been recently
used, 6 of 45 (13%) children with a record of recently pre-
scribed azithromycin carried an azithromycin-resistant
strain compared to 5 of 70 (7%) children with no record
of recently prescribed azithromycin (RD = 6% [-5, 18]).
Antibiotic-resistant serotypes
Penicillin resistance (MIC> = 0.12 μg/mL) was found in
both 7PCV and non-7PCV serotypes (Figure 2). In 2003,
34% of 137 resistant isolates were serotype 19A and in
2005, 26% (of 112 isolates) were 19A. Of 24 resistant iso-
lates in Central Australia in 2005 9 (38%) were serotype
19A. Serotype 16F accounted for 7% in 2003 and 19% in
2005.
Macrolide resistance (azithromycin MIC ≥ 2 μg/mL) was
found mainly in the non-7PCV serotypes (Figure 2). Eight
Proportion of children with nasopharyngeal carriage of pneumococcal serotypes, by 7PCV and 23PPV serotype group and yearFigure 1
Proportion of children with nasopharyngeal carriage of pneumococcal serotypes, by 7PCV and 23PPV sero-
type group and year. Significant reductions in 6B and 19A from 2003 to 2005. Significant increases in 20,9N,23B, 34,10F 
from 2003 to 2005.
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Proportion of children with nasopharyngeal carriage of pneumococcal serotypes and antimicrobial non-susceptible serotypes, 7PCV and 23PPV serotype groupFigure 2
Proportion of children with nasopharyngeal carriage of pneumococcal serotypes and antimicrobial non-sus-
ceptible serotypes, 7PCV and 23PPV serotype group. A: 2003. B: 2005. Serogroups: Left – 7PCV serotypes. Middle – 
23PPV serotypes. Right – non-23PPV serotypes. MacR (yellow): azithromycin MIC ≥ 2 μg/mL. PenR (mauve): penicillin MIC ≥ 
0.12 μg/mL. Strains with resistance to both beta-lactam and macrolide antibiotics were included in each category. (in 2003 six 
of 38 6B isolates, two of 25 23Bs and one of 50 11As; in 2005 one of 39 23B isolates and one of 37 11As.)
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BMC Infectious Diseases 2009, 9:121 http://www.biomedcentral.com/1471-2334/9/121isolates with MIC > = 256 μg/mL were found in 6 commu-
nities in regions 1 and 2 in 2003. Serotypes were 16F(2)
and 6B(6).
Discussion
Our survey of 1720 young children in remote communi-
ties two and four years after commencement of a govern-
ment funded schedule for Indigenous children of 7PCV at
2, 4 and 6 months followed by a booster 23PPV at 18
months of age, provides a valuable source of pneumococ-
cal serotype and susceptibility data for the region. Two
major influences have had the potential to impact on
pneumococcal carriage in this population; pneumococcal
vaccination and antimicrobial prescribing. In three com-
munities studied extensively in the 1990s, around 50%
children carried 7PCV serotypes. Predominant pre-7PCV
serotypes were 6B, 19F, 23F, 19A, 16F and 6A (unpub-
lished data from 3 of the communities also in these sur-
veys). Retrospective PCR analysis confirms one of 20 pre-
7PCV 6A isolates was 6C.[15] A similar serotype distribu-
tion was found in cultures of discharge from acute perfo-
rations of the tympanic membrane.[16]
In general, this survey found small differences between
2003 and 2005. Vaccine uptake (at least 2 doses of 7PCV)
was around 87% in 2003 and increased to 96% in 2005.
By 2005, 84% age-eligible children had received 23PPV.
Between 2003 and 2005 we detected small but statistically
significant reductions in pneumococcal carriage (-6%).
This trend was consistent across all age groups. Similarly
for 7PCV types (-4%). There was a small reduction in 6A.
Overall, carriage of 23PPV-non-7PCV types was signifi-
cantly reduced (-5%), including serotype 19A (-4%), but
other 23PPV-non-7PCV types (20 and 9N) increased.
Non-vaccine serotypes (not in 23PPV) increased by 10%,
mainly attributable to serotypes 23B, 34 and 10F. Sero-
types 6C and 16F remained unchanged.
Among the group of children not vaccinated, 19A, 16F
and 6A and 6C were the predominant serotypes and 7PCV
type carriage was less than 10%, indicating a herd effect.
Similarly, in very young non-vaccinated infants (mean age
1.9 months) carriage was around 58% and only 8% car-
ried 7PCV vaccine types. Serotypes were diverse and no
dominant emerging serotype was evident in this young
group.
There is no strong evidence from 23PPV studies to suggest
that 23PPV has an impact on NP carriage[17] Our immu-
nogenicity study[18] showed 23PPV to be an effective
booster for 7PCV-primed serotypes, and that modest
responses to some additional serotypes in 23PPV also
occurred. Whether the antibody concentrations achieved
would prevent pneumococcal acquisition in the
nasopharynx was not assessed. In this survey we did detect
a 5% reduction in 23PPV-non-7PCV serotype carriage
between 2003 and 2005, at a time when uptake of 23PPV
as a booster dose increased from 35% to 62%. In the age
group eligible for 23PPV booster, carriage of serotypes
unique to 23PPV was actually higher in 23PPV-vaccinated
than non-vaccinated children, but only in 2003. We are
unable to explain this observation which was not present
in 2005. Whether this is related to lack of effect of 23PPV
on carriage, or timing of the swabbing in relation to
23PPV vaccination, or other factors cannot be assessed
from this study. Further studies of 23PPV seem warranted
as is large-scale surveillance of 23PPV-non-7PCV sero-
types in this population.
Beta-lactam prescribing did not change significantly
between 2003 and 2005, however the region with highest
prescribing also had higher carriage of penicillin non-sus-
ceptible strains. Serotypes 19A and 16F accounted for a
considerable proportion of beta-lactam- non-susceptible
strains, as did remaining 7PCV serotypes. The finding that
penicillin non-susceptibility is linked to the major
endemic replacement serotypes indicates a need for ongo-
ing monitoring to assess trends over coming years. High
level penicillin resistance was very uncommon in 2005 (1
isolate). The clinical impact of penicillin resistance will be
much greater if high level resistance increases over time. In
the 2008 report by Roche[3], serotype 19A caused the
majority (36%) of penicillin non-susceptible IPD cases in
Australia in 2006.
Macrolide prescribing was low, but increased significantly
between 2003 and 2005, mainly due to recent mass azi-
thromycin use in one community. At the time of our sur-
vey in that community there was no statistically
significant difference in pneumococcal carriage or carriage
of azithromycin resistant strains between children
recently prescribed azithromycin and those not (RD = 6%
[-5, 18]). Our previous longitudinal study[19] had shown
that azithromycin reduces carriage of pneumococci, pro-
viding resistant strains with a selective advantage that
allows spread within the community. Over time, and in
the absence of further azithromycin use or selective pres-
sure, susceptible stains re-populate and the proportion of
the population carrying resistant strains declines.[19] The
present cross-sectional study does not capture this
dynamic process and therefore does not allow any conclu-
sions regarding the relationship between mass azithromy-
cin use and carriage. In Central Australia, recent macrolide
prescribing was rare, but carriage of azithromycin resistant
strains was clearly higher than other regions. We suggest
that this higher background of resistance may be related to
a longer period of exposure to azithromycin for tra-
choma[20] and STI (sexually transmitted infection)[21]
eradication programs, in the central Australian region.
Data to support this are lacking; the 2006 Trachoma sur-Page 7 of 9
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was recommended but was poorly documented in the
Northern Territory[20]
Whilst carriage prevalence does not fully predict IPD sero-
types (particularly outbreak or epidemic serotypes such as
serotypes 1 or 5), the majority of annual IPD cases are
caused by the serotypes most prevalent in the carriage
population. In Australia, rates of IPD caused by serotype
19A in Indigenous children have fluctuated over recent
years and serotype 6A became the most common non-vac-
cine IPD serotype in Indigenous children and the second
most common in non-Indigenous children.[3]
Hanna[22] compared IPD serotypes in under 5 year old
Indigenous children living in far North Queensland pre-
and post-7PCV implementation. They concluded that
there was no evidence of non-7PCV serotype replacement.
However, the pre-vaccine non-7PCV cases were inflated
by a serotype 1 outbreak. Excluding type 1 cases, there was
a risk difference in non-7PCV IPD of 55% [95%CI 30,80].
Reporting of pneumococcal epidemiology needs to con-
sider the epidemic and endemic nature of various sero-
types and that serotype-specific data are needed to best
describe and prepare for shifts over time and in response
to vaccines and antibiotic selective pressures.
Otitis media (OM) serotypes closely align with carriage
serotype profile,[23] and for Aboriginal children OM is a
common and serious infection often resulting in chronic
suppurative OM (CSOM). This study showed that the
serotypes colonising infants at 2 months of age, and there-
fore the serotypes most likely causing early OM,[24] are
no longer 7PCV-types. Vaccines that are effective in pre-
venting early onset of ear disease (and pneumonia) are
urgently needed.
Conclusion
Pneumococcal disease epidemiology is in a transition
period in Australia. This surveillance shows that nasal car-
riage of 7PCV serotypes has been replaced by the serotypes
that were the next most common carriage serotypes prior
to 7PCV use – namely 19A and 16F. Antibiotic resistance
is almost exclusively restricted to these serotypes (and
remaining 7PCV serotypes) and requires monitoring at
the regional level. The role of 23PPV in limiting carriage
and preventing disease in children also needs further
investigation. More work is needed to guide design of
appropriate surveillance systems that measure serotype
shifts and distinguish serotype replacement from secular
trends.
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